AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$33.71
+$0.21 (+0.64%) 4:00 PM ET
After hours$33.49
−$0.21 (−0.64%) 7:06 AM ET
Prev closePrevC$33.49
OpenOpen$33.49
Day highHigh$33.93
Day lowLow$33.38
VolumeVol65,941
Avg volAvgVol110,470
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$2.22B
Sector
Healthcare
AI report sections
MIXED
GLPG
Galapagos NV
Galapagos NV shows firm upward momentum over the past 6–12 months, with the price trading above key short-term moving averages and near the upper half of its 52-week range. Multiple technical tools (Bollinger, Donchian, Keltner, PSAR, Ichimoku) point to a constructive bullish pattern backdrop, though the RSI is elevated rather than oversold. Short interest is modest as a share of float but the high short volume ratio and limited disclosed fundamental and valuation data introduce uncertainty around the durability of the move.
AI summarized at 9:42 AM ET, 2025-12-23
AI summary scores
INTRADAY:63SWING:68LONG:55
Volume vs average
Intraday (cumulative)
−34% (Below avg)
Vol/Avg: 0.66×
RSI
46.41(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: -0.01 Signal: -0.01
Short-Term
-0.07 (Weak)
MACD: 0.11 Signal: 0.18
Long-Term
-0.07 (Weak)
MACD: 0.49 Signal: 0.56
Intraday trend score
48.80
LOW35.80HIGH48.80
Latest news
GLPG•12 articles•Positive: 2Neutral: 8Negative: 2
NeutralBenzinga• Rishabh Mishra
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED)
U.S. stock futures were mixed on Tuesday following Monday's rally that saw the Dow Jones jump nearly 600 points to an all-time high, driven by geopolitical developments in Venezuela. Key movers include CoreWeave rising on Nvidia partnership plans, Vistra gaining on a $4.7 billion acquisition, and Microchip Technology advancing on better-than-expected guidance. Treasury yields held steady at 4.17% for the 10-year bond, with markets pricing in an 83.9% probability of unchanged Fed rates in January.
Stock climbed 5.99% after announcing the winding down of cell therapy activities following strategic review; while the stock price rose, the decision represents a strategic retreat rather than growth.
NeutralGlobeNewswire Inc.• Galapagos Nv
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
Galapagos NV reported promising Phase 2 results for GLPG5101, a CAR T-cell therapy for mantle cell lymphoma, showing 100% objective response rate and 96% complete response rate with minimal toxicity. However, the company intends to wind down its cell therapy activities.
Positive clinical trial results are offset by the company's decision to wind down cell therapy activities, resulting in a balanced sentiment
NeutralGlobeNewswire Inc.• Galapagos Nv
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025
Galapagos reported promising phase 2 results for GLPG5101, a CAR T-cell therapy for mantle cell lymphoma, showing 100% objective response rate and 96% complete response rate. The company simultaneously announced its intention to wind down cell therapy activities.
Positive clinical trial results are offset by the strategic decision to wind down cell therapy activities, resulting in a balanced sentiment
NeutralGlobeNewswire Inc.• Galapagos Nv
Galapagos Receives Transparency Notifications from Bank of America
Bank of America Corporation crossed and then fell below the 5% voting rights threshold for Galapagos NV on November 12 and 14, 2025, respectively, following acquisition and disposal of voting rights and financial instruments.
Routine disclosure of shareholding changes without significant negative or positive implications
NeutralGlobeNewswire Inc.• Galapagos Nv
Galapagos ontvangt transparantieverklaringen van Bank of America
Bank of America Corporation filed transparency declarations with Galapagos NV, indicating they crossed and then receded below the 5% voting rights threshold on November 12 and 14, 2025, respectively.
Routine disclosure of changes in stock ownership with no significant negative or positive implications
NegativeGlobeNewswire Inc.• Galapagos Nv
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onderdeel van de voortdurende transformatie van het bedrijf
Galapagos NV plans to gradually discontinue its cell therapy activities after a strategic evaluation, aiming to improve operational efficiency and pursue new business development opportunities. The decision may impact approximately 365 employees across Europe, US, and China.
Company is winding down cell therapy activities, potentially closing multiple international facilities and reducing workforce by 365 employees, indicating significant organizational restructuring and potential financial challenges
NegativeGlobeNewswire Inc.• Galapagos Nv
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
Galapagos NV plans to wind down its cell therapy business after a strategic review found no viable proposals for the business. The company intends to reallocate resources towards pursuing transformative business development opportunities, potentially impacting approximately 365 employees across multiple global sites.
Company is closing its cell therapy business, reducing workforce by 365 employees, and expecting significant restructuring costs between €250-325 million, indicating substantial organizational challenges
PositiveGlobeNewswire Inc.• N/A
Galapagos Appoints Aaron Cox as Chief Financial Officer
Galapagos NV announced the appointment of Aaron Cox as their new Chief Financial Officer, effective July 7, 2025. Cox brings over two decades of leadership experience in the biotechnology and capital markets sectors, having previously served as Executive Vice President and CFO at Horizon Therapeutics.
GLPGGalapagosHorizon TherapeuticsCFObiotechnologycorporate financeM&Abusiness development
Sentiment note
The article highlights Galapagos' appointment of an experienced CFO, Aaron Cox, who is expected to play a key role in accelerating the company's pipeline growth and transforming the business.
PositiveGlobeNewswire Inc.• N/A
Galapagos benoemt Aaron Cox als Chief Financial Officer
Galapagos has appointed Aaron Cox, former CFO of Horizon Therapeutics, as its new Chief Financial Officer. Cox brings extensive experience in biotechnology, capital markets, and mergers and acquisitions. He will play a key role in accelerating Galapagos' pipeline growth and value creation.
GLPGAMGNGalapagosHorizon TherapeuticsCFObiotechnologymergers and acquisitions
Sentiment note
The article highlights Galapagos' appointment of an experienced CFO, Aaron Cox, who is expected to contribute to the company's growth and value creation. This suggests a positive outlook for Galapagos.
NeutralGlobeNewswire Inc.• N/A
Planisware expands into Belgium to support the sustained growth of its business in the Benelux region
Planisware, a leading B2B provider of SaaS, is expanding into Belgium to strengthen its presence in the Benelux region, where it has seen a significant increase in business over the past four years.
Galapagos is mentioned as one of Planisware's leading clients in the Benelux region, but no additional information is provided about the company's performance or relationship with Planisware.
NeutralGlobeNewswire Inc.• N/A
Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025
Galapagos NV, a global biotechnology company, announced the departure of its CFO and COO, Thad Huston, effective August 1, 2025. Huston is leaving the company for personal and professional reasons after joining in 2023 to support Galapagos' transformation into a cell therapy company.
GLPGGalapagos NVCFOCOOcell therapy
Sentiment note
The article announces the departure of a key executive, which could have both positive and negative implications for the company. However, the overall tone is neutral as the company is actively working to find a successor and ensure a smooth transition.
NeutralGlobeNewswire Inc.• N/A
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
Galapagos NV announced the departure of its CFO and COO, Thad Huston, effective August 1, 2025. Huston is leaving the company to return to the U.S. for personal and professional reasons. Galapagos expects to announce Huston's successor in the coming months.
The article announces the departure of a key executive, which could be seen as a neutral event as the company expects to find a suitable successor.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
